

Communication

# Enhancement of Transgene Expression by Mild Hypothermia is Promoter-Dependent in HEK293 Cells

Min Ho Jang <sup>†</sup>, Honggi Min <sup>†</sup> and Jae Seong Lee <sup>\*</sup>

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea;  
minho00123@ajou.ac.kr (M.H.J.); minhk96@ajou.ac.kr (H.M.)

<sup>\*</sup> Correspondence: jaeseonglee@ajou.ac.kr

<sup>†</sup> These authors contributed equally to this work.

## Supplementary Materials

**Table S1.** List of common transcription factors identified from comparison of *in silico* analysis of CMV-enhancer specific transcription factors and significant DEG lists from RNA-seq analysis.

Gene Symbol	Gene Description	Fold Change (32 °C versus 37 °C)
<i>FOS</i>	Fos proto-oncogene, AP-1 transcription factor subunit	-3.86 ( $3.25 \times 10^{-34}$ )
<i>RFX3</i>	regulatory factor X3	-2.22 ( $8.52 \times 10^{-6}$ )
<i>PRRX2</i>	paired related homeobox 2	-2.03 ( $5.42 \times 10^{-3}$ )
<i>FOSL1</i>	FOS like 1, AP-1 transcription factor subunit	-4.51 ( $1.94 \times 10^{-10}$ )
<i>LBX2</i>	ladybird homeobox 2	-3.00 ( $3.23 \times 10^{-6}$ )
<i>JDP2</i>	Jun dimerization protein 2	-4.31 ( $1.80 \times 10^{-22}$ )
<i>NEUROG2</i>	neurogenin 2	2.17 ( $3.71 \times 10^{-7}$ )
<i>EBF1</i>	EBF transcription factor 1	-2.06 ( $1.97 \times 10^{-3}$ )
<i>ETV1</i>	ETS variant 1	-2.67 ( $8.10 \times 10^{-8}$ )
<i>ETV2</i>	ETS variant 2	2.61 ( $2.35 \times 10^{-4}$ )
<i>NKX3-1</i>	NK3 homeobox 1	2.59 ( $6.02 \times 10^{-18}$ )
<i>ONECUT3</i>	one cut homeobox 3	-3.08 ( $3.41 \times 10^{-6}$ )
<i>HOXD9</i>	homeobox D9	-2.25 ( $1.59 \times 10^{-13}$ )
<i>INSM1</i>	INSM transcriptional repressor 1	-3.03 ( $1.68 \times 10^{-12}$ )



**Table S2.** Primer sequences used for RT-PCR and RT-qPCR.


Gene	Direction	Sequence (5'-3')
<i>ACTB</i>	Forward	CTGGAACGGTGAAGGTGACA
	Reverse	AAGGGACTCCTGTAACAACGCA
<i>ETV2</i> isoform 1	Forward	AGCAGAGACATGCTGGAAAG
	Reverse	GGAACTTCTGGGTGCAGTAA
<i>ETV2</i> isoform 2	Forward	CGCACGGACTGTACCATT
	Reverse	GCTCTGGTACCGCTTCAA
<i>NEUROG2</i>	Forward	CTGGGTCTGGTACACGATTG
	Reverse	CAGTCTACGGGTCTTCTGATG
<i>NKX3-1</i>	Forward	CGGAGACCCAAGTGAAGATATG
	Reverse	CAAAGAGGAGTGCTTCTCAA

**Table S3.** Comparison of fold changes in DEGs identified by RNA-seq and RT-qPCR.

Gene	Fold Change of DEGs (32 °C versus 37 °C)	
	RNA-seq (raw p-value)	RT-qPCR <sup>a</sup>
<i>ETV2</i>	2.61 ( $2.35 \times 10^{-4}$ )	1.36/1.12 <sup>b</sup>
<i>NEUROG2</i>	2.17 ( $3.71 \times 10^{-7}$ )	1.24
<i>NKX3-1</i>	2.59 ( $6.02 \times 10^{-18}$ )	2.02

<sup>a</sup> Human *ACTB* gene was used as a reference gene. Average values obtained in triplicate experiments are shown. <sup>b</sup> *ETV2* isoform 1 / *ETV2* isoform 2.

**Figure S1.** Representative flow cytometry plots and gates of CRISPR/Cas9-mediated targeted integration of promoter sequences at the AAVS1 locus shown in Figure 1B.**Figure S2.** Schematic representation of the short variants of the CMV promoter. Predicted binding sites of NKX3-1 on the CMV-enhancer region are shown.

**A****Figure S3.** Original gel images.